Bladder Cancer Coverage from Every Angle
Editor:
Thomas Flaig, MD
Advertisement
Advertisement

Videos

Sumanta K. Pal, MD: Does Adding Berzosertib to Chemotherapy Improve Outcomes in Urothelial Carcinoma?

Enrique Grande, MD, PhD, on Results From IMvigor130: Atezolizumab Plus Platinum-Based Chemotherapy for Urothelial Cancer

Arlene O. Siefker-Radtke, MD, on Comparing Immunotherapy and Antibody-Drug Conjugates for Urothelial Bladder Cancer

Tracy L. Rose, MD, on Clinical Implications of Treating Bladder Cancer With Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab

Thomas Powles, MD, PhD, on Enfortumab Vedotin-ejfv: New Standard of Care for Aggressive Urothelial Carcinoma?

Daniel M. Geynisman, MD, on a Strategic Approach to Neoadjuvant Treatment of Bladder Cancer

Monika Joshi, MD, on After the DUART Trial: Next Steps in Treating Urothelial Cancer of the Bladder

Aristotelis Bamias, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Syed A. Hussain, MD, on Neoadjuvant Treatment With Nintedanib for Locally Advanced Disease

Thomas Flaig, MD, on Advances in Bladder Cancer Treatment: Expert Perspective

Thomas Flaig, MD, on NCCN Clinical Practice Guidelines in Oncology®: Their Increasing Importance in Bladder Cancer

Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Petros Grivas, MD, PhD, on Urothelial Carcinoma Roundup: Expert Perspective

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials

Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.